Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 505 to 514 of 514 entries
Sorted by: Best Match Show Resources per page
Sex Differences in the Behavioral, Molecular, and Structural Effects of Ketamine Treatment in Depression.

The international journal of neuropsychopharmacology

Ponton E, Turecki G, Nagy C.
PMID: 34894233
Int J Neuropsychopharmacol. 2022 Jan 12;25(1):75-84. doi: 10.1093/ijnp/pyab082.

Major depressive disorder (MDD) is a common psychiatric illness that manifests in sex-influenced ways. Men and women may experience depression differently and also respond to various antidepressant treatments in sex-influenced ways. Ketamine, which is now being used as a...

Cite
Ponton E, Turecki G, Nagy C. Sex Differences in the Behavioral, Molecular, and Structural Effects of Ketamine Treatment in Depression. Int J Neuropsychopharmacol. 2022;25(1):75-84doi: 10.1093/ijnp/pyab082.
Ponton, E., Turecki, G., & Nagy, C. (2022). Sex Differences in the Behavioral, Molecular, and Structural Effects of Ketamine Treatment in Depression. The international journal of neuropsychopharmacology, 25(1), 75-84. https://doi.org/10.1093/ijnp/pyab082
Ponton, Ethan, et al. "Sex Differences in the Behavioral, Molecular, and Structural Effects of Ketamine Treatment in Depression." The international journal of neuropsychopharmacology vol. 25,1 (2022): 75-84. doi: https://doi.org/10.1093/ijnp/pyab082
Ponton E, Turecki G, Nagy C. Sex Differences in the Behavioral, Molecular, and Structural Effects of Ketamine Treatment in Depression. Int J Neuropsychopharmacol. 2022 Jan 12;25(1):75-84. doi: 10.1093/ijnp/pyab082. PMID: 34894233.
Copy Download .nbib Format: NLM
Drug-oxidizing and conjugating non-cytochrome P450 (non-P450) enzymes in cynomolgus monkeys and common marmosets as preclinical models for humans.

Biochemical pharmacology

Uno Y, Uehara S, Yamazaki H.
PMID: 34968483
Biochem Pharmacol. 2021 Dec 27;197:114887. doi: 10.1016/j.bcp.2021.114887. Epub 2021 Dec 27.

Many drug oxidations and conjugations are mediated by a variety of cytochromes P450 (P450) and non-P450 enzymes in humans and non-human primates. These non-P450 enzymes include aldehyde oxidases (AOX), carboxylesterases (CES), flavin-containing monooxygenases (FMO), glutathione S-transferases (GST), arylamine N-acetyltransferases...

Cite
Uno Y, Uehara S, Yamazaki H. Drug-oxidizing and conjugating non-cytochrome P450 (non-P450) enzymes in cynomolgus monkeys and common marmosets as preclinical models for humans. Biochem Pharmacol. 2021;197:114887doi: 10.1016/j.bcp.2021.114887.
Uno, Y., Uehara, S., & Yamazaki, H. (2021). Drug-oxidizing and conjugating non-cytochrome P450 (non-P450) enzymes in cynomolgus monkeys and common marmosets as preclinical models for humans. Biochemical pharmacology, 197114887. https://doi.org/10.1016/j.bcp.2021.114887
Uno, Yasuhiro, et al. "Drug-oxidizing and conjugating non-cytochrome P450 (non-P450) enzymes in cynomolgus monkeys and common marmosets as preclinical models for humans." Biochemical pharmacology vol. 197 (2021): 114887. doi: https://doi.org/10.1016/j.bcp.2021.114887
Uno Y, Uehara S, Yamazaki H. Drug-oxidizing and conjugating non-cytochrome P450 (non-P450) enzymes in cynomolgus monkeys and common marmosets as preclinical models for humans. Biochem Pharmacol. 2021 Dec 27;197:114887. doi: 10.1016/j.bcp.2021.114887. Epub 2021 Dec 27. PMID: 34968483.
Copy Download .nbib Format: NLM
Ongoing and potential novel trends of pomegranate fruit peel; a comprehensive review of its health benefits and future perspectives as nutraceutical.

Journal of food biochemistry

Fahmy HA, Farag MA.
PMID: 34923641
J Food Biochem. 2022 Jan;46(1):e14024. doi: 10.1111/jfbc.14024. Epub 2021 Dec 19.

Pomegranate is an ancient shrub, globally distributed nowadays. It has been used in the middle east as a medicinal food and traditional medicine for thousands of years. Pomegranate peel (PP) constitutes about 50% of the total fruit, however, it...

Cite
Fahmy HA, Farag MA. Ongoing and potential novel trends of pomegranate fruit peel; a comprehensive review of its health benefits and future perspectives as nutraceutical. J Food Biochem. 2021;46(1):e14024doi: 10.1111/jfbc.14024.
Fahmy, H. A., & Farag, M. A. (2022). Ongoing and potential novel trends of pomegranate fruit peel; a comprehensive review of its health benefits and future perspectives as nutraceutical. Journal of food biochemistry, 46(1), e14024. https://doi.org/10.1111/jfbc.14024
Fahmy, Heba A, and Farag, Mohamed A. "Ongoing and potential novel trends of pomegranate fruit peel; a comprehensive review of its health benefits and future perspectives as nutraceutical." Journal of food biochemistry vol. 46,1 (2022): e14024. doi: https://doi.org/10.1111/jfbc.14024
Fahmy HA, Farag MA. Ongoing and potential novel trends of pomegranate fruit peel; a comprehensive review of its health benefits and future perspectives as nutraceutical. J Food Biochem. 2022 Jan;46(1):e14024. doi: 10.1111/jfbc.14024. Epub 2021 Dec 19. PMID: 34923641.
Copy Download .nbib Format: NLM
Current production by non-methanotrophic bacteria enriched from an anaerobic methane-oxidizing microbial community.

Biofilm

Berger S, Shaw DR, Berben T, Ouboter HT, In 't Zandt MH, Frank J, Reimann J, Jetten MSM, Welte CU.
PMID: 34308332
Biofilm. 2021 Jun 15;3:100054. doi: 10.1016/j.bioflm.2021.100054. eCollection 2021 Dec.

In recent years, the externalization of electrons as part of respiratory metabolic processes has been discovered in many different bacteria and some archaea. Microbial extracellular electron transfer (EET) plays an important role in many anoxic natural or engineered ecosystems....

Cite
Berger S, Shaw DR, Berben T, et al. Current production by non-methanotrophic bacteria enriched from an anaerobic methane-oxidizing microbial community. Biofilm. 2021;3:100054doi: 10.1016/j.bioflm.2021.100054.
Berger, S., Shaw, D. R., Berben, T., Ouboter, H. T., In 't Zandt, M. H., Frank, J., Reimann, J., Jetten, M. S. M., & Welte, C. U. (2021). Current production by non-methanotrophic bacteria enriched from an anaerobic methane-oxidizing microbial community. Biofilm, 3100054. https://doi.org/10.1016/j.bioflm.2021.100054
Berger, S, et al. "Current production by non-methanotrophic bacteria enriched from an anaerobic methane-oxidizing microbial community." Biofilm vol. 3 (2021): 100054. doi: https://doi.org/10.1016/j.bioflm.2021.100054
Berger S, Shaw DR, Berben T, Ouboter HT, In 't Zandt MH, Frank J, Reimann J, Jetten MSM, Welte CU. Current production by non-methanotrophic bacteria enriched from an anaerobic methane-oxidizing microbial community. Biofilm. 2021 Jun 15;3:100054. doi: 10.1016/j.bioflm.2021.100054. eCollection 2021 Dec. PMID: 34308332; PMCID: PMC8258643.
Copy Download .nbib Format: NLM
Alisertib shows negligible potential for perpetrating pharmacokinetic drug-drug interactions on ABCB1, ABCG2 and cytochromes P450, but acts as dual-activity resistance modulator through the inhibition of ABCC1 transporter.

Toxicology and applied pharmacology

Vagiannis D, Zhang Y, Budagaga Y, Novotna E, Skarka A, Kammerer S, Küpper JH, Hofman J.
PMID: 34896433
Toxicol Appl Pharmacol. 2021 Dec 09;434:115823. doi: 10.1016/j.taap.2021.115823. Epub 2021 Dec 09.

Alisertib (MLN8237), a novel Aurora A kinase inhibitor, is currently being clinically tested in late-phase trials for the therapy of various malignancies. In the present work, we describe alisertib's potential to perpetrate pharmacokinetic drug-drug interactions (DDIs) and/or to act...

Cite
Vagiannis D, Zhang Y, Budagaga Y, et al. Alisertib shows negligible potential for perpetrating pharmacokinetic drug-drug interactions on ABCB1, ABCG2 and cytochromes P450, but acts as dual-activity resistance modulator through the inhibition of ABCC1 transporter. Toxicol Appl Pharmacol. 2021;434:115823doi: 10.1016/j.taap.2021.115823.
Vagiannis, D., Zhang, Y., Budagaga, Y., Novotna, E., Skarka, A., Kammerer, S., Küpper, J. H., & Hofman, J. (2021). Alisertib shows negligible potential for perpetrating pharmacokinetic drug-drug interactions on ABCB1, ABCG2 and cytochromes P450, but acts as dual-activity resistance modulator through the inhibition of ABCC1 transporter. Toxicology and applied pharmacology, 434115823. https://doi.org/10.1016/j.taap.2021.115823
Vagiannis, Dimitrios, et al. "Alisertib shows negligible potential for perpetrating pharmacokinetic drug-drug interactions on ABCB1, ABCG2 and cytochromes P450, but acts as dual-activity resistance modulator through the inhibition of ABCC1 transporter." Toxicology and applied pharmacology vol. 434 (2021): 115823. doi: https://doi.org/10.1016/j.taap.2021.115823
Vagiannis D, Zhang Y, Budagaga Y, Novotna E, Skarka A, Kammerer S, Küpper JH, Hofman J. Alisertib shows negligible potential for perpetrating pharmacokinetic drug-drug interactions on ABCB1, ABCG2 and cytochromes P450, but acts as dual-activity resistance modulator through the inhibition of ABCC1 transporter. Toxicol Appl Pharmacol. 2021 Dec 09;434:115823. doi: 10.1016/j.taap.2021.115823. Epub 2021 Dec 09. PMID: 34896433.
Copy Download .nbib Format: NLM
Alisertib shows negligible potential for perpetrating pharmacokinetic drug-drug interactions on ABCB1, ABCG2 and cytochromes P450, but acts as dual-activity resistance modulator through the inhibition of ABCC1 transporter.

Toxicology and applied pharmacology

Vagiannis D, Zhang Y, Budagaga Y, Novotna E, Skarka A, Kammerer S, Küpper JH, Hofman J.
PMID: 34896433
Toxicol Appl Pharmacol. 2021 Dec 09;434:115823. doi: 10.1016/j.taap.2021.115823. Epub 2021 Dec 09.

Alisertib (MLN8237), a novel Aurora A kinase inhibitor, is currently being clinically tested in late-phase trials for the therapy of various malignancies. In the present work, we describe alisertib's potential to perpetrate pharmacokinetic drug-drug interactions (DDIs) and/or to act...

Cite
Vagiannis D, Zhang Y, Budagaga Y, et al. Alisertib shows negligible potential for perpetrating pharmacokinetic drug-drug interactions on ABCB1, ABCG2 and cytochromes P450, but acts as dual-activity resistance modulator through the inhibition of ABCC1 transporter. Toxicol Appl Pharmacol. 2021;434:115823doi: 10.1016/j.taap.2021.115823.
Vagiannis, D., Zhang, Y., Budagaga, Y., Novotna, E., Skarka, A., Kammerer, S., Küpper, J. H., & Hofman, J. (2021). Alisertib shows negligible potential for perpetrating pharmacokinetic drug-drug interactions on ABCB1, ABCG2 and cytochromes P450, but acts as dual-activity resistance modulator through the inhibition of ABCC1 transporter. Toxicology and applied pharmacology, 434115823. https://doi.org/10.1016/j.taap.2021.115823
Vagiannis, Dimitrios, et al. "Alisertib shows negligible potential for perpetrating pharmacokinetic drug-drug interactions on ABCB1, ABCG2 and cytochromes P450, but acts as dual-activity resistance modulator through the inhibition of ABCC1 transporter." Toxicology and applied pharmacology vol. 434 (2021): 115823. doi: https://doi.org/10.1016/j.taap.2021.115823
Vagiannis D, Zhang Y, Budagaga Y, Novotna E, Skarka A, Kammerer S, Küpper JH, Hofman J. Alisertib shows negligible potential for perpetrating pharmacokinetic drug-drug interactions on ABCB1, ABCG2 and cytochromes P450, but acts as dual-activity resistance modulator through the inhibition of ABCC1 transporter. Toxicol Appl Pharmacol. 2021 Dec 09;434:115823. doi: 10.1016/j.taap.2021.115823. Epub 2021 Dec 09. PMID: 34896433.
Copy Download .nbib Format: NLM
Gut microbiome affects the metabolism of metronidazole in mice through regulation of hepatic cytochromes P450 expression.

PloS one

Zemanová N, Lněničková K, Vavrečková M, Anzenbacherová E, Anzenbacher P, Zapletalová I, Hermanová P, Hudcovic T, Kozáková H, Jourová L.
PMID: 34752478
PLoS One. 2021 Nov 09;16(11):e0259643. doi: 10.1371/journal.pone.0259643. eCollection 2021.

Microbiome is now considered as a significant metabolic organ with an immense potential to influence overall human health. A number of diseases that are associated with pharmacotherapy interventions was linked with altered gut microbiota. Moreover, it has been reported...

Cite
Zemanová N, Lněničková K, Vavrečková M, et al. Gut microbiome affects the metabolism of metronidazole in mice through regulation of hepatic cytochromes P450 expression. PLoS One. 2021;16(11):e0259643doi: 10.1371/journal.pone.0259643.
Zemanová, N., Lněničková, K., Vavrečková, M., Anzenbacherová, E., Anzenbacher, P., Zapletalová, I., Hermanová, P., Hudcovic, T., Kozáková, H., & Jourová, L. (2021). Gut microbiome affects the metabolism of metronidazole in mice through regulation of hepatic cytochromes P450 expression. PloS one, 16(11), e0259643. https://doi.org/10.1371/journal.pone.0259643
Zemanová, Nina, et al. "Gut microbiome affects the metabolism of metronidazole in mice through regulation of hepatic cytochromes P450 expression." PloS one vol. 16,11 (2021): e0259643. doi: https://doi.org/10.1371/journal.pone.0259643
Zemanová N, Lněničková K, Vavrečková M, Anzenbacherová E, Anzenbacher P, Zapletalová I, Hermanová P, Hudcovic T, Kozáková H, Jourová L. Gut microbiome affects the metabolism of metronidazole in mice through regulation of hepatic cytochromes P450 expression. PLoS One. 2021 Nov 09;16(11):e0259643. doi: 10.1371/journal.pone.0259643. eCollection 2021. PMID: 34752478; PMCID: PMC8577747.
Copy Download .nbib Format: NLM
Prediction of cytochromes P450 3A and 2C19 modulation by both inflammation and drug interactions using physiologically based pharmacokinetics.

CPT: pharmacometrics & systems pharmacology

Lenoir C, Niederer A, Rollason V, Desmeules JA, Daali Y, Samer CF.
PMID: 34791831
CPT Pharmacometrics Syst Pharmacol. 2022 Jan;11(1):30-43. doi: 10.1002/psp4.12730. Epub 2021 Nov 17.

Xenobiotics can interact with cytochromes P450 (CYPs), resulting in drug-drug interactions, but CYPs can also contribute to drug-disease interactions, especially in the case of inflammation, which downregulates CYP activities through pretranscriptional and posttranscriptional mechanisms. Interleukin-6 (IL-6), a key proinflammatory...

Cite
Lenoir C, Niederer A, Rollason V, et al. Prediction of cytochromes P450 3A and 2C19 modulation by both inflammation and drug interactions using physiologically based pharmacokinetics. CPT Pharmacometrics Syst Pharmacol. 2021;11(1):30-43doi: 10.1002/psp4.12730.
Lenoir, C., Niederer, A., Rollason, V., Desmeules, J. A., Daali, Y., & Samer, C. F. (2022). Prediction of cytochromes P450 3A and 2C19 modulation by both inflammation and drug interactions using physiologically based pharmacokinetics. CPT: pharmacometrics & systems pharmacology, 11(1), 30-43. https://doi.org/10.1002/psp4.12730
Lenoir, Camille, et al. "Prediction of cytochromes P450 3A and 2C19 modulation by both inflammation and drug interactions using physiologically based pharmacokinetics." CPT: pharmacometrics & systems pharmacology vol. 11,1 (2022): 30-43. doi: https://doi.org/10.1002/psp4.12730
Lenoir C, Niederer A, Rollason V, Desmeules JA, Daali Y, Samer CF. Prediction of cytochromes P450 3A and 2C19 modulation by both inflammation and drug interactions using physiologically based pharmacokinetics. CPT Pharmacometrics Syst Pharmacol. 2022 Jan;11(1):30-43. doi: 10.1002/psp4.12730. Epub 2021 Nov 17. PMID: 34791831.
Copy Download .nbib Format: NLM
Targeted Lipidomic Analysis of Aqueous Humor Reveals Signaling Lipid-Mediated Pathways in Primary Open-Angle Glaucoma.

Biology

Azbukina NV, Chistyakov DV, Goriainov SV, Kotelin VI, Fedoseeva EV, Petrov SY, Sergeeva MG, Iomdina EN, Zernii EY.
PMID: 34356513
Biology (Basel). 2021 Jul 13;10(7). doi: 10.3390/biology10070658.

Primary open-angle glaucoma (POAG) is characterized by degeneration of retinal ganglion cells associated with an increase in intraocular pressure (IOP) due to hindered aqueous humor (AH) drainage through the trabecular meshwork and uveoscleral pathway. Polyunsaturated fatty acids and oxylipins...

Cite
Azbukina NV, Chistyakov DV, Goriainov SV, et al. Targeted Lipidomic Analysis of Aqueous Humor Reveals Signaling Lipid-Mediated Pathways in Primary Open-Angle Glaucoma. Biology (Basel). 2021;10(7)doi: 10.3390/biology10070658.
Azbukina, N. V., Chistyakov, D. V., Goriainov, S. V., Kotelin, V. I., Fedoseeva, E. V., Petrov, S. Y., Sergeeva, M. G., Iomdina, E. N., & Zernii, E. Y. (2021). Targeted Lipidomic Analysis of Aqueous Humor Reveals Signaling Lipid-Mediated Pathways in Primary Open-Angle Glaucoma. Biology, 10(7), . https://doi.org/10.3390/biology10070658
Azbukina, Nadezhda V, et al. "Targeted Lipidomic Analysis of Aqueous Humor Reveals Signaling Lipid-Mediated Pathways in Primary Open-Angle Glaucoma." Biology vol. 10,7 (2021). doi: https://doi.org/10.3390/biology10070658
Azbukina NV, Chistyakov DV, Goriainov SV, Kotelin VI, Fedoseeva EV, Petrov SY, Sergeeva MG, Iomdina EN, Zernii EY. Targeted Lipidomic Analysis of Aqueous Humor Reveals Signaling Lipid-Mediated Pathways in Primary Open-Angle Glaucoma. Biology (Basel). 2021 Jul 13;10(7). doi: 10.3390/biology10070658. PMID: 34356513; PMCID: PMC8301454.
Copy Download .nbib Format: NLM
Acquisition of Dynamic Light Scattering Device for Nanoparticle Characterization (Small Equipment Proposal).

[No authors listed]
UIID-NSF: 379

Over the past decade there has been a dramatic increase in the use of human-engineered nanoparticles in manufacturing, electronics, food safety, and consumer products. It is important, therefore, to understand the impact of nanomaterials on the environment. State-of-the-art equipment...

Cite
Acquisition of Dynamic Light Scattering Device for Nanoparticle Characterization (Small Equipment Proposal). ;
(). Acquisition of Dynamic Light Scattering Device for Nanoparticle Characterization (Small Equipment Proposal). .
"Acquisition of Dynamic Light Scattering Device for Nanoparticle Characterization (Small Equipment Proposal)." vol. ().
Acquisition of Dynamic Light Scattering Device for Nanoparticle Characterization (Small Equipment Proposal). UIID-NSF: 379.
Copy Download .nbib Format: NLM
Showing 505 to 514 of 514 entries